Full-Time
Clinical Supply Project Manager
Packaging and Labelling
Posted on 2/23/2026
Eurofins
10,001+ employees
Global lab testing and analytics network
No salary listed
Liverpool, UK
In Person
 Business & Strategy (1) |
|---|
- BSc degree in Life Sciences, Information Technology, or a related field; significant relevant experience may be considered in place of formal educational qualifications
- Experience in clinical supplies project management, with exposure to GMP-regulated environments and an understanding of compliance expectations in clinical supply chains
- Strong problem-solving skills and ability to work effectively with cross-functional and geographically dispersed teams to resolve issues, prioritise tasks, and maintain delivery timelines in a fast-paced and evolving environment
- Excellent communication and interpersonal skills, with the ability to collaborate effectively with colleagues, stakeholders, and external partners; capability to develop and share knowledge related to clinical trial label generation and production
- Proficiency in working with materials requirements planning systems such as SAP and ability to maintain accuracy across all project documentation, scheduling, and operational activities
- As a Project Manager, you will support the delivery of clinical supplies by effectively managing assigned clinical packaging projects and liaising closely with Trial Supply Managers on all aspects of packaging and labelling design, production scheduling, SAP demand entry, material creation, and associated purchasing activities
- You will manage multiple projects simultaneously, coordinating all required deliverables such as product information, codes, and label text to align with production schedules. You will develop detailed time and event plans, monitor progress against key milestones, and communicate issues to the appropriate management level in a timely manner
- You will generate internal packaging and labelling instructions and label print production orders in alignment with clinical protocol requirements and relevant regulatory standards. You will create and release BOMs and process orders within SAP for assigned projects, ensuring all order details are accurate and compliant
- You will be responsible for sourcing labels from approved suppliers and supporting external packaging and labelling activities at designated vendors, ensuring adherence to master service, technical, and quality agreements, and monitoring vendor performance metrics
- You will work collaboratively with Clinical Supply Operations, Analytical, and Quality teams to support on‑time testing and material release, ensuring all activities within your remit meet GMP and regulatory standards. You will report deviations promptly, support investigations, and contribute to maintaining the CSO Risk Register
- You will contribute to the preparation and review of procedural documents, ensuring processes remain current, compliant with GMP expectations, aligned with higher‑level procedural requirements, and reflective of best business practices. You will also support continual process improvement initiatives and ensure project management and outsourcing operations remain sustainable by developing and sharing subject‑matter expertise across the team
Eurofins provides global laboratory testing and analytical services to verify the safety, authenticity, and quality of products across food, water, medicine, and the environment. It operates a network of more than 900 laboratories in over 60 countries, offering access to more than 200,000 analytical methods. Its product work involves running specialized tests—using chemistry, biology, and other scientific techniques—to confirm origin, composition, and compliance of samples, such as detecting wine fraud or contaminant presence. The company differentiates itself through its massive, distributed lab network and broad portfolio, enabling standardized testing at scale and fast turnaround across many industries, rather than relying on a single specialty or location. Its goal is to protect public health and safety by delivering accurate, comprehensive testing data and helping clients meet regulatory and quality requirements.
Company Size
10,001+
Company Stage
IPO
Headquarters
Luxembourg
Founded
1987
Simplify's Take
What believers are saying
- $147M Lancaster expansion adds 300,000 sq ft biopharma facility by 2029.
- CMP partnership launches CR3520 cIEF-MS services March 2026.
- Alphora consortium develops high-yield ADC platform February 2026.
What critics are saying
- Data breach fallout triggers lawsuits, loses health contracts in 6 months.
- UL Solutions acquisition strips MET Labs expertise April 2026.
- €3,641M debt breaches covenants if growth falters by FY 2027.
What makes Eurofins unique
- SNIF-NMR® patented in 1987 detects wine fraud via origin verification.
- Over 900 labs in 62 countries offer 200,000 analytical methods.
- Acquisition strategy since 1997 builds global bio-analytical dominance.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Company News
CMP Scientific and Eurofins BPT China Laboratory announce strategic collaboration to deliver advanced CE-MS services for biopharmaceutical characterization. CMP Scientific Corp Feb 11, 2026, 11:15 ET The partnership expands access to state-of-the-art cIEF-MS and CZE-MS workflows, supporting recombinant protein therapeutics across research, development, and regulatory submissions, with direct molecular identification of charge variants and impurities. BROOKLYN, N.Y., Feb. 11, 2026 /PRNewswire-PRWeb/ - CMP Scientific today announced a strategic collaboration with Eurofins BioPharma Product Testing China Laboratory to provide advanced capillary electrophoresis - mass spectrometry (CE-MS) services for comprehensive characterization of biopharmaceutical products to customers worldwide. As part of this collaboration, CMP Scientific has begun providing its proprietary CR3520 online cIEF-MS charge variant analysis workflow to support biopharmaceutical development and BLA submissions for Eurofins' clients. In addition, CMP Scientific will implement its EMASS-II CE-MS technology within Eurofins Laboratories, where it will be integrated with multiple high-resolution mass spectrometry platforms to create an instrument-agnostic CE-MS capability. This approach is designed to maximize the performance and flexibility of each mass spectrometer system while delivering robust, high-quality CE-MS data. "At CMP Scientific, our mission is to empower biopharmaceutical laboratories with world-class CE-MS analytical workflows," said Dr. James Xia, CEO of CMP Scientific. "We're excited to collaborate with Eurofins to make high-performance CE-MS technologies more broadly accessible. By combining CMP's CE-MS expertise with Eurofins' powerful analytical services infrastructure, we enable researchers to gain deeper molecular insights and accelerate biopharmaceutical development." Mr. Ang Zhang, General Manager of Eurofins BPT China, stated: "This collaboration reflects Eurofins' continued commitment to providing cutting-edge analytical solutions for innovative biopharmaceutical and biotechnology companies. Through our partnership with CMP Scientific, we are expanding access to advanced and reliable CE-MS analytical workflows, thereby enhancing our capabilities in characterizing complex biomolecules." The new CE-MS analysis services, including CR3520 online cIEF-MS charge variant analysis and CZE-MS peak identification for CE-SDS impurity analysis, are expected to be available to Eurofins customers starting in March 2026, initially launched at the Eurofins BPT Shanghai laboratory. These services will provide advanced analytical strategies to support recombinant protein therapeutic products during research, development, and regulatory submission phases, enabling a "what you see is what you identify" approach and elevating charge variant and impurity analysis to a whole new level. Traditional cIEF and CE-SDS are "non-mass spectrometry" methods based on migration time or UV detection. While they offer excellent separation, their ability to identify peaks is limited, usually relying on comparison with standards or inference. For example, cIEF separates charge variants based on isoelectric point (pI), but if specific details of the variants (such as deamidation, glycosylation, C-terminal lysine heterogeneity, pyroglutamate cyclization, fragmentation, aggregation, etc.) need to be identified, offline MS analysis of collected fractions is required. This process involves complex fraction collection, desalting, and re-injection, which is not only cumbersome and time-consuming but also prone to errors. The CR3520 online cIEF-MS charge variant analysis can not only separate the main peak and multiple micro-heterogeneity peaks but also immediately obtain precise molecular weight information for each charge variant, thus directly identifying the type of modification causing the charge difference. Furthermore, in forced degradation or stability studies, the CR3520 online cIEF-MS charge variant analysis can observe the trend of specific modifications (such as deamidation) over time and under different conditions, directly correlating them with pI shifts, providing direct evidence for understanding protein degradation pathways. The situation with CE-SDS is similar. Traditional CE-SDS uses SDS and coated capillaries, relying solely on migration time and molecular weight standards for identification, and is not compatible with MS. CMP Scientific has developed an innovative CZE-MS method system. Through improved ion source interfaces and buffer systems (such as using MS-friendly surfactants or avoiding direct entry of SDS into the mass spectrometer), they have successfully achieved the identification and analysis of CE-SDS-related components, representing a significant technological breakthrough. For fragment peaks in non-reducing CE-SDS, it is possible to directly determine whether they are light chain (LC), heavy chain (HC), F(ab')2, or Fc fragments. For reducing CE-SDS, it can identify whether it is the complete light chain, heavy chain, or non-glycosylated heavy chain, etc. This provides irrefutable evidence for impurity tracing (such as enzyme cleavage sites) in process development. This technology can also be used to confirm covalent modifications that cause apparent molecular weight changes. For example, different drug-to-antibody ratio (DAR) species in ADC drugs will exhibit different migration patterns in non-reducing CE-SDS. CZE-MS can directly identify the DAR value corresponding to each peak and correlate it with the UV chromatogram. About CMP Scientific CMP Scientific is a leading innovator in analytical instrumentation, specializing in capillary electrophoresis and CE-MS interfaces that enable advanced biomolecular analysis. The company's proprietary CE-MS technology integrates high-efficiency CE separation with high-resolution mass spectrometry, enabling comprehensive characterization of biopharmaceutical products across both CZE-MS and cIEF-MS workflows. About Eurofins BioPharma Product Testing China Laboratory Eurofins BioPharma Product Testing (EBPT) is the biopharmaceutical testing division of the Eurofins Group, operating one of the world's largest unified GMP biopharmaceutical product testing laboratory networks. EBPT provides comprehensive analytical testing services to pharmaceutical, biopharmaceutical, and medical device companies worldwide. With more than 42 laboratories globally, EBPT delivers consistent, high-quality testing through a harmonized quality system, centralized billing model, and deep global regulatory expertise. EBPT China operates two laboratories in Shanghai, specializing in full-lifecycle analytical testing and method development for large-molecule therapeutics, including proteins, ADCs, vaccines, and cell and gene therapies. The team has extensive experience supporting drug development and regulatory submissions and is widely recognized for its strong industry reputation. Media Contact SOURCE CMP Scientific Corp
Eurofins CDMO Alphora joins international consortium project to advance next generation ADC expression platform. Business Wire In this article: MISSISSAUGA, Ontario, February 05, 2026-(BUSINESS WIRE)-Eurofins CDMO Alphora is pleased to announce that its Canadian-based division is receiving advisory services and funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support a research and development collaboration project focused on advancing a transformative approach for next-generation ADC (antibody-drug conjugate) production to meet the growing demand for targeted therapeutics. As part of this initiative, Eurofins CDMO Alphora (Canada) is collaborating with Daresbury Proteins Ltd. (UK) to contribute its development and manufacturing expertise to the NextGen ADC Platform: Engineering High Yielding Expression Vectors and Peptide Linker Tags for Advanced ADC Production initiative. This ground breaking project aims to develop a novel, high yield expression platform that integrates optimized affinity peptide tags directly into monoclonal antibody (mAb) production. By engineering these tags into the expression system itself, the platform streamlines antibody - drug conjugate (ADC) manufacturing by eliminating several traditional conjugation and purification steps. The resulting process is designed to reduce ADC manufacturing complexity and cost while accelerating development timelines. Looking ahead, the initiative aims to lay the foundation for future production of clinic-ready ADCs designed for efficient point-of-care reconstitution, with the potential to generate significant benefits across clinical and commercial supply chains. By combining Eurofins CDMO Alphora's proven capabilities in complex drug development and manufacturing with specialized protein expression technology from Daresbury Proteins Ltd., and support from NRC IRAP, the project is positioned to drive forward innovative solutions, foster highly-skilled job creation, and support Canada's capacity to produce the next wave of precision biologics. About Eurofins CDMO Alphora Eurofins CDMO Alphora, part of an international network of Eurofins Scientific, develops and manufactures small molecule & biologic drug substances and drug products "under one roof" in Mississauga, Ontario, Canada. Our small molecule capabilities include the development and manufacture of API's and HPAPI's, oral drug products and API solid-state R&D. Our biologics capabilities include the development and manufacture of mAbs, proteins and ADCs, and Sterile Fill (2026). Established in 2003, our FDA, Health Canada, and Japan PMDA inspected site has over 250 people.
Eurofins announces nearly $150 million expansion to Lancaster County lab. Eurofins Lancaster Laboratories on Monday announced that it will add a new 300,000-square-foot biopharmaceutical testing facility and office to its Leola campus, costing about $147 million and adding about 250 jobs over the next three years. Neal Salerno, senior vice president of Eurofins BioPharma Product Testing, said he's been working with state officials to plan the project for the past year. "From our humble roots as a small food testing lab, Eurofins is now the number one testing organization, ensuring that the air you breathe, the water you drink, the food you eat, the medicine you take and the medical devices that you use are safe," Salerno said during a news conference on Monday. Lancaster Laboratories was founded in 1961 and provides testing services for biopharmaceutical and pharmaceutical products. In 2011, Belgium-based Eurofins purchased the company. A collection of interviews, photos, and music videos, featuring local musicians who have stopped by the WITF performance studio to share a little discussion and sound. Produced by WITF's Joe Ulrich. Salerno did not provide a specific timeline for the project. During the announcement, he was surrounded by state and local officials, as well as Eurofins scientists in white lab coats. Gov. Josh Shapiro was on hand to announce his administration would provide more than $2 million to help fund the project. "We're not only helping bring more crucial testing to more people - we're creating more new opportunities for folks here in Lancaster," the first-term Democrat said. "We know that when we invest in a company like Eurofins, we're also having a positive downstream impact on industries that rely on the testing Eurofins provides." The state dollars going toward the projects, according to state Secretary of Community and Economic Development Rick Siger, are almost entirely - about $1.8 million - from a Pennsylvania First Fund grant. Another $375,000, Siger said, would come from the WEDnetPA grant program and would go toward on-the-job training for new employees. Eurofins' latest planned expansion would mark its largest to date, after a five-story, $42 million space opened in 2019. For that project, the state provided the company about $1 million in grant money and $1 million in tax credits. Ezra Rothman, president of EDC Lancaster, celebrated Eurofins' announcement. He pointed to the company's partnership with local educational institutions, like Millersville University, to say students will have a direct "pipeline" to "highly technical, future-oriented jobs." A political economy. Shapiro heavily stressed the positive economic impact that Eurofins' expansion for Lancaster County and Pennsylvania, broadly. "This is a company that quite literally is the leader in the world," Shapiro said. "And so it means they can be anywhere in the world, but they've chosen to be here in Lancaster." Shapiro is a rumored contender for the Democratic Party's 2028 presidential nomination, and in recent months has increasingly voiced his opposition to President Donald Trump's handling of the economy. Shapiro pointed to several positive economic outlooks for Pennsylvania: Moody's rated it as the only state in the northeast with a growing economy, and Forbes named it one of the best states in the country to start a business. His words at Eurofins come after posting weeks' worth of criticism toward Trump and Vice President JD Vance, who both separately visited Pennsylvania this month to tout the federal administration's economic record. The Bureau of Labor Statistics' report this month found unemployment reached 4.6% in November, from 4% at the beginning of Trump's term in January. And between October and November, the U.S. has lost more than 40,000 net jobs, though November saw jobs added to the economy. Help support the information and news you've come to rely on in central Pennsylvania. with a donation to WITF.
Eurofins Medical Device Services launches first GMP PFAS screening and testing solutions for medical devices. LANCASTER, Pa., December 02, 2025-(BUSINESS WIRE)-Eurofins Medical Device Services North America, part of a global network of over 20 medical device testing laboratories and a leading medical device solutions partner, recently launched a GMP PFAS testing and screening solution, the first developed and commercialized for the medical device industry. This offering provides insights to medical device manufacturers as they navigate the complex and evolving global regulations surrounding PFAS, ultimately contributing to medical device and patient safety. Per- and polyfluoroalkyl substances, or PFAS, are a group of more than twenty thousand chemical compounds which are highly resistant to degradation and have been found to pose potential threats to human health and the environment. Implementing PFAS testing in the early development stages allows medical device manufacturers to prepare for potential regulatory updates and avoid future shutdowns, recalls, and liability issues, while further supporting their sustainability goals. Eurofins Medical Device Services North America's GMP PFAS testing and screening solution includes: * Combustion Ion Chromatography (CIC) for total organic fluorine screening in solids, liquids, and gases, to provide an initial assessment of PFAS levels. * Process mapping and supply chain audits, to identify contamination pathways. * Solvent extraction and direct combustion for flexible sample formats. * Extractables & Leachables (E&L) testing, toxicological risk assessments, and aging studies. * Stability and forced degradation studies, to identify PFAS breakdown products. Eurofins Medical Device Services North America operates under ISO 17025 accreditation standards, and applies GMP best practices, ensuring sensitivity, specificity, and reproducibility even at trace levels. Learn more at https://www.eurofins.com/medical-device/ About Eurofins Medical Device Services Eurofins Medical Device Services offers comprehensive testing, consulting, and regulatory support for Class I, II, and III medical devices - including implants, instruments, single-use and combination products, and wearables. With more than 40 years of experience, our global network of medical device testing laboratories and consultants provide strategic guidance from biological evaluation plans through commercialization, and specialize in international regulatory requirements, scientific trends, and tailored testing strategies. Committed to global standards, Eurofins Medical Device Services designs and executes testing plans aligned with ISO, ASTM, ANSI, and AAMI standards, as well as custom methodologies. Our quality systems meet GMP and ISO 17025 requirements, helping clients accelerate market access with confidence.
Eurofins Sustainability Services introduces Chem-ST(TM) for Toys: the first testing programme to streamline global compliance and ensure full chemical safety in toys.